Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 20, 2026

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models
08:44

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Published on: November 11, 2014

8.6K

Isolating potentiated Hsp104 variants using yeast proteinopathy models.

Meredith E Jackrel1, Amber Tariq1, Keolamau Yee1

  • 1Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania.

Journal of Visualized Experiments : Jove
|November 20, 2014
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revision Medialization Thyroplasty for Glottic Insufficiency Amid Rapid Weight Loss on Semaglutide.

The Laryngoscope·2026
Same author

Hypoxia rescues complex 1-associated disease caused by proteostatic defects.

Nature metabolism·2026
Same author

RNA G-quadruplexes function as a tunable switch of FUS phase separation.

Nucleic acids research·2026
Same author

Isoform-specific steric zippers drive aberrant assembly and mislocalization of shortened TDP-43.

Science advances·2026
Same author

High-throughput screening approach identifies substrate-selective Hsp104 variants that counter amyloid seeding with diminished off-target effects.

Molecular cell·2026
Same author

Short RNA chaperones promote aggregation-resistant TDP-43 conformers to mitigate neurodegeneration.

Science (New York, N.Y.)·2026

Researchers engineered yeast Hsp104 protein variants to combat neurodegenerative diseases. These enhanced variants effectively suppress toxic protein aggregation, offering a new therapeutic strategy for conditions like ALS and Parkinson's disease.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Molecular Biology

Background:

  • Protein misfolding disorders, including amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), are characterized by toxic protein aggregation.
  • Budding yeast (Saccharomyces cerevisiae) serves as a valuable model organism for studying these disorders due to its ability to recapitulate key pathological features.
  • Protein disaggregases, such as yeast Hsp104, show potential for reversing protein misfolding, but native Hsp104 has limited efficacy against human disease-associated aggregates.

Purpose of the Study:

  • To engineer enhanced variants of the yeast Hsp104 protein with improved disaggregase activity.
  • To develop and optimize screening methods for identifying Hsp104 variants that suppress proteotoxicity in yeast models of neurodegenerative diseases.
  • To investigate the potential of engineered Hsp104 variants in reversing the aggregation and toxicity of disease-linked proteins like TDP-43, FUS, and α-synuclein.

More Related Videos

High-throughput Screening for Protein-based Inheritance in S. cerevisiae
08:12

High-throughput Screening for Protein-based Inheritance in S. cerevisiae

Published on: August 8, 2017

6.8K
Growth Assays to Assess Polyglutamine Toxicity in Yeast
09:06

Growth Assays to Assess Polyglutamine Toxicity in Yeast

Published on: March 5, 2012

14.0K

Related Experiment Videos

Last Updated: Apr 20, 2026

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models
08:44

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Published on: November 11, 2014

8.6K
High-throughput Screening for Protein-based Inheritance in S. cerevisiae
08:12

High-throughput Screening for Protein-based Inheritance in S. cerevisiae

Published on: August 8, 2017

6.8K
Growth Assays to Assess Polyglutamine Toxicity in Yeast
09:06

Growth Assays to Assess Polyglutamine Toxicity in Yeast

Published on: March 5, 2012

14.0K

Main Methods:

  • Utilized budding yeast (Saccharomyces cerevisiae) as a model system to express and screen protein variants.
  • Developed a robust two-step screening protocol to identify Hsp104 variants that suppress proteotoxicity while minimizing false positives.
  • Constructed and screened large libraries of Hsp104 variants for their ability to mitigate the toxic effects and aggregation of TDP-43, FUS, and α-synuclein.

Main Results:

  • Identified a series of potentiated Hsp104 variants demonstrating potent suppression of TDP-43, FUS, and α-synuclein toxicity and aggregation in yeast.
  • The optimized screening protocol effectively eliminated nonspecific suppression, ensuring the identification of genuine suppressors.
  • Demonstrated the feasibility of engineering Hsp104 for therapeutic applications against protein misfolding disorders.

Conclusions:

  • Engineered Hsp104 variants represent a promising therapeutic avenue for neurodegenerative proteinopathies.
  • The developed screening methodology is adaptable for discovering suppressors of various toxic proteins in yeast.
  • This research provides a foundation for developing novel strategies to combat protein misfolding diseases.